Moderna (MRNA) PT Lowered to $78 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $258.38 --0%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $78.00 (from $96.00) while maintaining a Buy rating.
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
- GXO Logistics Inc. (GXO) PT Raised to $73 at JPMorgan
- Freshpet (FRPT) PT Raised to $78 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
